Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of GH001 in Healthy Subjects
NCT06511947Phase 1Terminated
- Sponsor
- GH Research PLC
- Start
- Aug 2024
- Primary completion
- Mar 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mebufotenin in major depressive disorder (MDD) (11 cohorts), sponsored by GH Research PLC. Primary endpoints: Maximum Observed Serum Concentration up to 6 hours, Time of Maximum Observed Serum Concentration up to 6 hours and 16 more. Started Aug 2024; status: terminated.
02
Drugs
mebufotenin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06511947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06511947.